May 29, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Press Release on Audited Financial Results for the quarter and year ended March 31, 2025

With reference to the captioned subject; we, Zota Health Care Limited are forwarding herewith enclosed a copy of press release on Audited Financial Results for the quarter and year ended March 31, 2025.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

ASHVIN BHAGAVANBHAI VARIYA
Digitally signed by ASHVIN BHAGAVANBHAI VARIYA
Date: 2025.05.29 20:51:12 +05'30'

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: Press Release

Registered Office:
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

zota healthcare ltd.

PRESS RELEASE
Q4FY25/FY25

Zota Health Care Limited Achieves Remarkable 62% YoY Revenue Growth in FY25 Reaching ₹29,298 Lakhs

Q4FY25 Revenues grew to ₹ 9,728 lakhs: 96% YoY growth; Gross profit stood at ₹4,940 lakhs; 84% YoY growth.

Q4FY25 DavaIndia-GMV stood at ₹ 7,682 Lakhs

Surat, 29th May 2025:

Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the Fourth quarter & Full Year ended 31st March 2025.

FY25 Business Highlights:

Particulars	FY25			FY24		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of Davaindia stores*	852	730	1582	253	627	880
Full Year Footfall (lakhs)	55.1	42.6	97.7	20.7	31.1	51.8
GMV (₹ lakhs)	₹ 12,568	₹ 11,994	₹ 24,562	₹ 5,063	₹ 8,703	₹ 13,766
Average wallets spend (₹)	₹ 228	₹ 282	-	₹ 245	₹ 280	-

As on 31st March 2025

Q4FY25 Business Highlights:

Particulars	Q4FY25			Q4FY24		
	COCO	FOFO	Total	COCO	FOFO	Total
Quarterly Footfall (lakhs)	19.0	11.9	30.9	6.9	8.9	15.8
GMV (₹ lakhs)	₹ 4,297	₹ 3,385	₹ 7,682	₹ 1,660	₹ 2,465	₹ 4,125
Average wallets spend (₹)	₹ 227	₹ 285		₹ 241	₹ 278	-

As on 31st March 2025

Key Operational & Financial Highlights:

- Added 702 new stores during the year FY25 with 599 COCO & 103 FOFO stores.

FY25

- Revenue from operation was ₹ 29,298 lakhs for FY25 compared to ₹ 18,048 lakhs in FY24, an increase of 62% YoY.
- Gross Profit stood at ₹ 15,567 lakhs compared to ₹ 8,379 lakhs during FY24, a significant increase of 86% YoY.

Q4FY25

- Revenue from operation was ₹ 9,727 lakhs for Q4FY25 compared to ₹ 4,964 lakhs in Q4FY24, an increase of 96% YoY.
- Gross Profit stood at ₹ 4,940 lakhs compared to ₹ 2,685 lakhs during Q4FY24, a significant increase of 84%.

Commenting on the FY25 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said,

"FY2025 truly stood out as a milestone year for Davaindia, marked by meaningful progress in our mission to make affordable healthcare more accessible across India. A major highlight was the strong expansion of our Company-Owned Company-Operated (COCO) store network, alongside the successful launch of our

Davaindia B2C online portal and mobile app, offering customers a seamless, doorstep delivery experience for essential medicines.

*During the year, we added **702 new stores**, including **599 COCO** and **103 FOFO** outlets, strengthening our presence in both urban and underserved regions. As part of our long-term strategy for sustainable growth, we are intensifying our focus on self-operated COCO stores, with an ambitious goal of launching ~ 800 to 900 additional stores by FY26. On the FY25 performance front, we're proud of the momentum we've built: Gross Merchandise Value (GMV) reached ₹24,562 lakhs, Customer footfalls rose to ~98 lakhs, Total consolidated revenue jumped 62% YoY to ₹29,298 lakh & Gross profit grew by 86% YoY, reaching ₹15,567 lakh.*

As we look ahead, our mission remains clear: sustaining this growth by widening our footprint, improving store-level efficiencies and stay true to our vision of making healthcare not just accessible, but truly affordable for all."

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 470 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Mr. Ashvin Variya	Mr. Siddesh Chawan	Mr. Ajit Mishra
CS, Zota Health Care Ltd	Ernst & Young LLP, Investor Relations	Ernst & Young LLP, Investor Relations
E: cszota@zotahealthcare.com	E: Siddesh.Chawan@in.ey.com	E: Ajit.J.Mishra@in.ey.com

Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.